0001213900-20-012942.txt : 20200519 0001213900-20-012942.hdr.sgml : 20200519 20200519163020 ACCESSION NUMBER: 0001213900-20-012942 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200519 DATE AS OF CHANGE: 20200519 EFFECTIVENESS DATE: 20200519 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Intec Pharma Ltd. CENTRAL INDEX KEY: 0001638381 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-367324 FILM NUMBER: 20894050 BUSINESS ADDRESS: STREET 1: 12 HARTOM STREET STREET 2: HAR HOTZVIM CITY: JERUSALEM STATE: L3 ZIP: 777512 BUSINESS PHONE: 97225864657 MAIL ADDRESS: STREET 1: 12 HARTOM STREET STREET 2: HAR HOTZVIM CITY: JERUSALEM STATE: L3 ZIP: 777512 D 1 primary_doc.xml X0708 D LIVE 0001638381 Intec Pharma Ltd. 12 HARTOM STREET HAR HOTZVIM JERUSALEM L3 ISRAEL 777512 97225864657 ISRAEL None None Corporation true JEFFREY A. MECKLER 12 HARTOM STREET HAR HOTZVIM JERUSALEM L3 ISRAEL 9777512 Executive Officer Director NADAV NAVON 12 HARTOM STREET HAR HOTZVIM JERUSALEM L3 ISRAEL 9777512 Executive Officer WALT A LINSCOTT 12 HARTOM STREET HAR HOTZVIM JERUSALEM L3 ISRAEL 9777512 Executive Officer NIR SASSI 12 HARTOM STREET HAR HOTZVIM JERUSALEM L3 ISRAEL 9777512 Executive Officer R. MICHAEL GENDREAU 12 HARTOM STREET HAR HOTZVIM JERUSALEM L3 ISRAEL 9777512 Executive Officer JOHN W. KOZARICH 12 HARTOM STREET HAR HOTZVIM JERUSALEM L3 ISRAEL 9777512 Director HILA W. KARAH 12 HARTOM STREET HAR HOTZVIM JERUSALEM L3 ISRAEL 9777512 Director ANTHONY J. MADDALUNA 12 HARTOM STREET HAR HOTZVIM JERUSALEM L3 ISRAEL 9777512 Director WILLIAM B. HAYES 12 HARTOM STREET HAR HOTZVIM JERUSALEM L3 ISRAEL 9777512 Director ROGER J. POMERANTZ 12 HARTOM STREET HAR HOTZVIM JERUSALEM L3 ISRAEL 9777512 Director Pharmaceuticals Decline to Disclose 06b false 2020-05-04 false true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 PARK AVENUE 4TH FLOOR NEW YORK NY NEW YORK 10022 CA CALIFORNIA IL ILLINOIS NY NEW YORK TX TEXAS false 5000000 5000000 0 The warrants and shares underlying the warrants, the subject matter of this Form D, were issued in connection with an offering of (i)16,291,952 shares issued in a registered direct offering, and (ii)unregistered warrants to purchase up to 8,145,976 shares false 4 350000 0 H.C. Wainwright is also entitled to a management fee equal to 1.0% of the gross proceeds raised in this offering and a non-accountable expense reimbursement of $75,000. 0 Issuer expects to use proceeds from the offering to fund its research and development activities and for working capital and general corporate purposes, which includes payment of salaries to the named executive officers. false Intec Pharma Ltd. /s/ Nir Sassi Nir Sassi Chief Financial Officer 2020-05-19